JP2025166240A5 - - Google Patents
Info
- Publication number
- JP2025166240A5 JP2025166240A5 JP2025138630A JP2025138630A JP2025166240A5 JP 2025166240 A5 JP2025166240 A5 JP 2025166240A5 JP 2025138630 A JP2025138630 A JP 2025138630A JP 2025138630 A JP2025138630 A JP 2025138630A JP 2025166240 A5 JP2025166240 A5 JP 2025166240A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- individual
- pharmaceutically acceptable
- acceptable carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971930P | 2020-02-08 | 2020-02-08 | |
| US62/971,930 | 2020-02-08 | ||
| US202063115975P | 2020-11-19 | 2020-11-19 | |
| US63/115,975 | 2020-11-19 | ||
| PCT/US2021/017113 WO2021159092A1 (en) | 2020-02-08 | 2021-02-08 | Compositions and methods for treating pompe disease |
| JP2022547874A JP7804582B2 (ja) | 2020-02-08 | 2021-02-08 | ポンペ病を処置するための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547874A Division JP7804582B2 (ja) | 2020-02-08 | 2021-02-08 | ポンペ病を処置するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025166240A JP2025166240A (ja) | 2025-11-05 |
| JP2025166240A5 true JP2025166240A5 (enExample) | 2026-04-06 |
Family
ID=74853758
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547874A Active JP7804582B2 (ja) | 2020-02-08 | 2021-02-08 | ポンペ病を処置するための組成物および方法 |
| JP2025138630A Pending JP2025166240A (ja) | 2020-02-08 | 2025-08-22 | ポンペ病を処置するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547874A Active JP7804582B2 (ja) | 2020-02-08 | 2021-02-08 | ポンペ病を処置するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12251430B2 (enExample) |
| EP (1) | EP4100120A1 (enExample) |
| JP (2) | JP7804582B2 (enExample) |
| KR (1) | KR20220139936A (enExample) |
| CN (1) | CN115715218A (enExample) |
| AU (1) | AU2021216055A1 (enExample) |
| BR (1) | BR112022015505A2 (enExample) |
| CA (1) | CA3167091A1 (enExample) |
| IL (1) | IL295415A (enExample) |
| MX (1) | MX2022009753A (enExample) |
| WO (1) | WO2021159092A1 (enExample) |
| ZA (1) | ZA202209925B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295415A (en) | 2020-02-08 | 2022-10-01 | Genzyme Corp | Compositions and methods for treating pompe disease |
| CN115916245A (zh) | 2020-06-14 | 2023-04-04 | 建新公司 | 用于治疗晚发型庞贝病的组合物和方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| CN102978185B (zh) * | 2007-01-18 | 2015-02-11 | 建新公司 | 包含氨基氧基基团的寡糖及其轭合物 |
| PL2889043T3 (pl) | 2008-12-16 | 2019-09-30 | Genzyme Corporation | Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko |
| MX2013013445A (es) | 2011-05-16 | 2014-07-28 | Genzyme Corp | Induccion de tolerancia inmunologica utilizando metotrexato. |
| WO2016149508A1 (en) * | 2015-03-19 | 2016-09-22 | Shire Human Genetic Therapies, Inc. | Mrna therapy for pompe disease |
| KR102747683B1 (ko) * | 2015-12-30 | 2024-12-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| IL295415A (en) | 2020-02-08 | 2022-10-01 | Genzyme Corp | Compositions and methods for treating pompe disease |
-
2021
- 2021-02-08 IL IL295415A patent/IL295415A/en unknown
- 2021-02-08 WO PCT/US2021/017113 patent/WO2021159092A1/en not_active Ceased
- 2021-02-08 US US17/170,667 patent/US12251430B2/en active Active
- 2021-02-08 CA CA3167091A patent/CA3167091A1/en active Pending
- 2021-02-08 EP EP21709562.9A patent/EP4100120A1/en active Pending
- 2021-02-08 AU AU2021216055A patent/AU2021216055A1/en active Pending
- 2021-02-08 MX MX2022009753A patent/MX2022009753A/es unknown
- 2021-02-08 CN CN202180013438.1A patent/CN115715218A/zh active Pending
- 2021-02-08 KR KR1020227030889A patent/KR20220139936A/ko active Pending
- 2021-02-08 BR BR112022015505A patent/BR112022015505A2/pt unknown
- 2021-02-08 JP JP2022547874A patent/JP7804582B2/ja active Active
-
2022
- 2022-09-06 ZA ZA2022/09925A patent/ZA202209925B/en unknown
-
2025
- 2025-02-13 US US19/053,240 patent/US20250319166A1/en active Pending
- 2025-08-22 JP JP2025138630A patent/JP2025166240A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Healy et al. | An association between recurrent oro‐genital ulceration and non‐steroidal anti‐inflammatory drugs | |
| CN117956995A (zh) | 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途 | |
| JP2021503468A5 (enExample) | ||
| JP2006514092A5 (enExample) | ||
| WO2021217702A1 (zh) | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 | |
| EP3395341A1 (en) | Composition for treating motor neuron diseases and use thereof | |
| CN109475554A (zh) | 基于脂核苷酸的ards治疗 | |
| BR112020018362A2 (pt) | Composição de glp-1 para tratar obesidade e controle de peso | |
| JP2021520396A5 (enExample) | ||
| GB2105191A (en) | Pharmaceutical formulations comprising human insulin and human proinsulin | |
| US5964224A (en) | Method for treating amyotrophic lateral sclerosis and a therapeutic agent therefor | |
| JP2022553888A5 (enExample) | ||
| US5886047A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
| JP2023544249A5 (enExample) | ||
| Güell et al. | Effects of a dopaminergic agonist (piribedil) on cerebral blood flow in man | |
| JP4800194B2 (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| JPWO2005110394A1 (ja) | 糖尿病治療薬 | |
| Uribe et al. | Cell kinetics of rat gastrointestinal mucosa Autoradiographic study after treatment with 15 (R) 15-methyl-prostaglandin E2 | |
| JP2022507528A5 (enExample) | ||
| CN121152634A (zh) | 用于治疗恶心和呕吐的方法和用途 | |
| Sawin et al. | 'Natural'Desiccated Thyroid: A'Health-food'Thyroid Preparation | |
| HAAS et al. | Experiences with α‐Ethyl‐α‐methylsuccinimide in the Treatment of Epilepsy | |
| CN1551778A (zh) | 用于糖尿病神经病变的药物组合物 | |
| Farag | Dexmedetomidine in the neurointensive care unit |